enGene Therapeutics Shares Surge Following Positive Mid-Stage Trial Data and Piper Sandler Upgrade
Shares of enGene Therapeutics (ENGN) rose approximately 20% on Thursday following the release of updated mid-stage clinical trial data for its lead therapeutic asset, detalimogene. The update, based on a data cut from October 29, provided positive insights into the treatment's efficacy for bladder cancer. In response to the clinical developments, Piper Sandler upgraded the stock, signaling increased confidence in the company's pipeline. This combination of clinical progress and analyst optimism has driven significant upward momentum for the Canadian biotechnology firm.
Tickers: $ENGN
Topics: biotechnology clinical trials stock upgrade
Read the full article at Seeking Alpha
Part of the story enGene Therapeutics Reports Positive Phase 2 LEGEND Trial Data for Detalimogene (2 articles)